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Abstract 
 
Inroduction: Nasal continuous positive airway pressure (NCPAP) is well established as a 
treatment for hyaline membrane disease (HMD) and other respiratory diagnoses in neonates.  
NCPAP is an affordable intervention which results in a reduction in the number of neonatal 
admissions to the intensive care unit (ICU) for ventilation.  At the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) we have been using NCPAP since April 2006.   
 
Objectives: The aim of this study was to review the use of early NCPAP in our hospital 
setting. 
 
Methods: This was a retrospective descriptive study of all neonates ≥ 750g admitted to 
CMJAH between 1st January 2013 and 31st July 2014 who received NCPAP within 72 hrs of 
birth.  The characteristics and the survival of all infants who received NCPAP was described 
using univariate analysis. 
 
Results: The NCPAP group (481) of neonates <1500g was significantly associated with 
surfactant use (p<0.0005), bronchopulmonary dysplasia (BPD) (p<0.0005) and late sepsis 
(p<0.0005).  The survival to day 7 and to discharge of infants treated with NCPAP was 
significantly decreased (p<0.0005). NCPAP alone (without ventilation), improved the 
survival to discharge (p=0.001).  The survival was 95.4% in the ≥1500g infants, compared to 
87.6% in the very low birth weight (VLBW) infants (1000-1499g) and 55.2% in the 
extremely low birth weight (ELBW) infants (750-999g).   
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Conclusion: NCPAP is an effective intervention for HMD; it is both cost effective and easy 
to use in a resource limited setting and reduces the morbidity and mortality associated with 
ICU admission. 
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Chapter 1:  
Introduction 
Nasal continuous positive airway pressure (NCPAP) has become widely used and accepted as 
a treatment for hyaline membrane disease (HMD) since its first introduction in 1971[1,2].  
HMD affects premature babies and causes considerable morbidity and mortality.  The use of 
NCPAP on its own and also in combination with the use of surfactant has been shown to 
improve the outcomes of HMD in premature infants [3].   
 
HMD [4] mainly occurs in neonates that are less than 34 weeks gestational age (GA).  The 
primary cause of HMD is a surfactant deficiency.  Surfactant is produced by the Type 2 
pneumocytes in the epithelial lining of the lungs.  Surfactant production begins at 24-28 
weeks gestation but is usually only detectable in amniotic fluid from 28-32 weeks.  Sufficient 
quantities of surfactant are usually only present from 34 weeks of gestation.  It is composed 
mainly of phospholipids (75%) and protein (10-15%).  The effect of surfactant is to reduce 
the surface tension of the alveoli and thus allow them to expand more easily and prevent 
alveolar collapse.  Without surfactant, there is progressive collapse of the alveoli and the 
small airways resulting in lung injury and atelectasis.  The cell damage causes the secretion 
of a proteinaceous exudate into the alveoli which characteristically stains as an eosinophilic 
hyaline membrane on pathology specimens [4].  In the premature neonate the respiratory 
distress is worsened by the presence of a compliant chest wall, as the large negative pressures 
needed to overcome the poor lung compliance cause chest retraction instead of lung inflation.   
 
The incidence of HMD is related to the degree of prematurity of the lungs and therefore the 
incidence increases as the gestational age decreases.  The use of antenatal steroids given to 
mothers where a premature delivery is expected has reduced the incidence and severity of 
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HMD [5].  The administration of surfactant for severe HMD has been shown to improve lung 
compliance, facilitate weaning off supplemental oxygen and results in fewer neonates 
needing ventilatory support.  Surfactant replacement therapy also significantly reduces the 
mortality from HMD [6].   
 
NCPAP is not only used in HMD but is also used to treat apnoea of prematurity, respiratory 
distress due to other aetiologies, some types of upper airway obstruction and can sometimes 
be used as an alternative to endotracheal intubation or as a weaning mode of ventilation [1].  
The continuous positive pressure provided by NCPAP helps to support and distend the 
alveoli, preventing their collapse.  There is a reduction in proximal airway resistance with a 
decrease in physiological dead space and NCPAP also improves the disorganized breathing 
pattern seen in neonates by supporting the diaphragm.  All of the above result in a reduction 
in the work of breathing in the neonate.  This results in the recruitment of alveoli which 
improves the ventilation perfusion mismatch of the lungs, and increases the functional 
residual capacity and tidal volume thereby improving oxygenation in the neonate [1].  NCPAP 
also exerts a distending pressure on the larger airways thus stabilizing them and preventing 
upper airway collapse [1].  The early use of NCPAP in premature neonates reduces the need 
for surfactant and results in fewer neonates needing to be intubated and ventilated [3, 7, 8].  This 
is both cost saving and also decreases ventilator induced lung injury and results in fewer 
cases of bronchopulmonary dysplasia (BPD) [3, 8].  Adverse effects of NCPAP use such as 
“CPAP belly syndrome” [9], nasal septal necrosis and pneumothorax may sometimes occur.   
 
NCPAP is an affordable intervention which is easy to use in a resource poor setting.  The 
successful use of NCPAP could result in a considerable reduction in the costs of neonatal 
care as there would be a reduction in ventilation and neonatal intensive care unit (NICU) 
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admissions as well as a decrease in poor outcomes associated with prolonged ventilation.  
Recently there have been a number of studies reporting on the survival of extremely low birth 
weight (ELBW) infants.  At Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) it 
was found that the use of NCPAP in ELBW infants was not associated with an improvement 
in survival [10].  This study was done using data from neonates ≤900g admitted between 
January 2006 and December 2010, a period during which fewer ELBW infants were 
receiving NCPAP than currently.  A previous study at CMJAH which assessed the 
determinants of survival in very low birth weight (VLBW) neonates (birth weight <1500g) 
found that NCPAP was associated with improved survival [11].  Kirsten et al [12] at the 
Tygerburg Children’s Hospital in the Western Cape found that NCPAP together with InSurE 
(where you intubate to give surfactant and then extubate) practiced in a neonatal high care 
ward with limited resources improved the survival of ELBW infants.   
 
NCPAP was introduced into the neonatal unit at the CMJAH in April 2006.  It is now used as 
the first line of ventilatory support in neonates with HMD.  We currently have 9 Bubble 
CPAP (Fisher and Paykel™) machines in our neonatal unit and due to such limited resources 
we are only offering NCPAP to neonates that weigh more than 750g.  The aim of this study 
was to review the use of early (within 72 hrs) NCPAP in neonates at CMJAH.     
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Chapter 2:  
Methods 
This was a retrospective descriptive study of all neonates with a birth weight ≥750g admitted 
to the neonatal unit at CMJAH between 1 January 2013 and 31 July 2014 who received 
NCPAP within 72hrs of birth.  Neonates were excluded if there was insufficient information, 
if NCPAP was used post extubation from conventional mechanical ventilation (CMV) or if 
they had major congenital abnormalities.  All in-born babies, babies born at midwife obstetric 
units (MOU), or born before arrival (BBA) were initially observed in the transitional care 
unit for assessment before being admitted to the neonatal unit and were included in our 
statistics.  T-piece resuscitators were not available in the labour ward nursery and bag mask 
valve resuscitation was used for babies who required resuscitation at birth.  The babies were 
observed for 1-2 hours in the transitional care unit and then a decision was made by the 
attending doctor on whether or not they required NCPAP and surfactant.  NCPAP with early 
rescue surfactant was offered to neonates with respiratory failure due to HMD as per the 
neonatal unit’s protocol.  Respiratory failure was defined as an oxygen saturation below 88% 
in 60% supplemental oxygen, respiratory acidosis on arterial blood gas or clinical signs of 
severe respiratory distress including indrawing of the sternum and tachypnoea.  Due to 
insufficient NCPAP machines, not all neonates who qualified for NCPAP could receive it.  
Neonates who required NCPAP were admitted to the high care neonatal ward where there 
were 9 Bubble NCPAP (Fisher and Paykel™) machines available; NCPAP was not initiated 
in NICU.  If NCPAP was not available, babies were given surfactant and placed on nasal 
prong oxygen.  The neonatal unit’s policy at the time of the study was that neonates’ ≥900g 
would qualify for ventilation in NICU if required. 
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2.1 Database: 
The neonatal records at CMJAH are kept on the REDCap (Research Electronic Data Capture) 
electronic neonatal database [13].   REDCap is a secure, web-based programme that has been 
designed to aid data capture for the purpose of clinical audit and quality improvement.  The 
data is collected upon discharge of patients and entered into the REDCap database.  The 
information is verified at several different stages of collection.  The following data were 
collected from the database: maternal data – antenatal steroids, place and mode of delivery, 
multiple gestation; infant data – gestational age, birth weight, gender, place of birth, 5 minute 
Apgar score, necrotising enterocolitis (NEC), intra-ventricular haemorrhage (IVH), NCPAP 
with or without surfactant or conventional mechanical ventilation (CMV), respiratory 
diagnosis, duration of NCPAP and ventilation, late sepsis (occurring after day 3), 
bronchopulmonary dysplasia (BPD) (defined by oxygen requirement at 28 days of age), nasal 
septal necrosis, pneumothorax, outcome (death or survival) at discharge.     
 
2.2 Statistical analysis: 
The data was entered into a MS Excel spreadsheet and imported into SPSS version 19, a 
statistical software package (http://www.spss.com).  Categorical variables were described 
using frequencies and percentages while continuous variables were described using mean and 
standard deviation.  The data were also stratified into birth weight categories (ELBW 
including 750-999g, VLBW including 1000-1499g, low birth weight (LBW) including 1500-
2499g and weights ≥2500g) and the proportion of infants in each category receiving NCPAP 
determined.  Neonates’ <1500g who had not received NCPAP were compared with those 
who had received NCPAP both for characteristics and survival to discharge.  Intraventricular 
haemorrhage (IVH) was graded according to the sonographic grading system described by 
Papile et al [14].  Grade 1 or 2 of IVH were considered together as “mild” and grade 3 or 4 as 
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“severe”.  The NEC category included grades 2 and 3 of NEC, according to the modified 
Bell’s staging criteria [15].  Infants were regarded as having birth asphyxia if they had Apgar 
scores of ≤ 5 at 5 minutes.  Babies on NCPAP who developed respiratory failure and required 
ventilation in NICU were regarded as having failed NCPAP.  The babies that were 
transferred out and those that were discharged home directly were grouped together as 
survivors for the purposes of analysis.  Univariate analysis was used to compare the 
characteristics of the two groups and survival was described.  Categorical variables were 
compared using Chi-squared tests and continuous variables using unpaired t-tests (as the 
distribution was normal).  A p-value of <0.05 was considered to be significant.  In neonates’ 
≥1500g, the characteristics, respiratory diagnosis and survival of infants who received 
NCPAP were described.    
 
2.3 Ethics: 
Ethics approval for the study was granted by the Committee for Research on Human Subjects 
at the University of the Witwatersrand, Johannesburg; clearance certificate number M140403 
(see Appendix B). 
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Chapter 3: 
 Results 
3.1 Infants <1500g: 
There were 748 VLBW infants admitted over the 19 month period.  Information was not 
available on 9 infants, 18 infants had major birth defects, NCPAP was used as a weaning 
mode of ventilation in 3 infants and NCPAP was started after >72hrs in 7 infants.  All of the 
above were excluded leaving a total of 711 infants in the study.   
The majority were females at 378 (53.2%).  The mean birth weight was 1158grams (SD 220) 
and GA was 29.5 weeks (SD 2.6).  The majority of infants (380 (53.4%)) were born by 
emergency caesarean section.  Most of the infants (591 (83.1%)) were inborn.  Antenatal 
steroids were given in 275 (38.7%) cases.  NCPAP was provided to 481 (67.7%) of the 
infants in total.  Most babies (397 (82.5%)) coped on NCPAP alone; in 84 (17.5%) infants 
NCPAP failed.  Overall there were 560 (78.8%) survivors.  The mean duration of NCPAP 
was 2.58 days (SD 3.52) with a maximum duration of 35 days.  Nasal septal necrosis 
occurred in 27/481 (5.6%) and pneumothorax occurred in 5/481 (1%) of the infants who 
received NCPAP.  Surfactant was given to 507 (71.3%) infants in total; 43 (8.4%) of these 
infants received surfactant without NCPAP.  Birth asphyxia occurred in 79 (11.1%) infants. 
 
3.1.1 VLBW 1000-1499g: 
In this category there were 517 infants, of whom 453 (87.6%) survived.  308 (59.6%) infants 
received NCPAP and surfactant was given to 329 (63.6%) infants.  There were 41 (8%) 
infants with birth asphyxia.  The use of NCPAP was significantly associated with death 
(p=0.001, OR 0.41, 95% CI 0.23-0.73).  252 (81.8%) infants coped on NCPAP alone, while 
56 (18.2%) infants failed NCPAP.   
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3.1.2 ELBW 750-999g: 
In this category there were 194 infants, of whom 107 (55.2%) survived.  173 (89.2%) infants 
received NCPAP and surfactant was given to 178 (91.8%) infants.  There were 38 (19.6%) 
infants with birth asphyxia.  NCPAP was not significantly associated with survival (p=0.261, 
OR 0.72, 95% CI 0.39-1.35).  145 (83.8%) infants coped on NCPAP alone, while 28 (16.1%) 
infants failed NCPAP (these were all >900g and thus were offered ventilation).   
 
3.1.3 NCPAP versus no NCPAP Group: 
The entire group of neonates 750g-1499g was divided into two: those who had received 
NCPAP and those who had not.  The characteristics of the two groups were compared and 
significant differences are shown in Table 1.  There was no significant difference in the 
babies with regards to CMV, pneumothorax, antenatal steroids, IVH or NEC.  Mild IVH 
occurred in 69 (14.4%) infants in the NCPAP group compared to 18 (7.8%) infants not 
receiving NCPAP and severe IVH occurred in 20 (4.2%) infants receiving NCPAP compared 
to 7 (3%) infants not receiving NCPAP. These differences were not significant.  The survival 
of the infants in the two groups was compared in Table 2. The use of NCPAP was associated 
with an increased risk of death by day 7 and at discharge.  There were 43 infants who 
demised between day 3 and day 7.  Within this group, 26 (60%) were under 1000g, 10 (23%) 
failed CPAP and needed CMV, 5 (2%) had NEC, 5 (2%) had sepsis and 4 (2%) had a severe 
grade of IVH.  When the successful use of NCPAP alone was compared to those who failed 
NCPAP, there was a significantly higher rate of survival to discharge.  This is shown in Table 
3.   
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 Table 1: Characteristics of the NCPAP group and no NCPAP group in neonates <1500g 
 
Variable NCPAP (481) No NCPAP (230) p-value 
Surfactant: 464 (96.4%) 43 (18.7%) <0.0005 
BPD: 108 (22.4%) 18 (7.8%) <0.0005 
Late Sepsis:  125 (25.9%) 30 (15%) <0.0005 
 
Table 2:  
The survival of infants who were treated with NCPAP compared to those without NCPAP in 
neonates <1500g 
 
 NCPAP (481) No NCPAP (230) p-value 
Survival to day 3 450 (93.5%) 222 (96.5%) 0.104 
Survival to day 7 407 (84.6%) 218 (94.7%) <0.0005 
Survival to 
discharge 
351 (72.8%) 209 (90.8%) <0.0005 
 
Table 3: The survival of infants who were treated with NCPAP alone in neonates <1500g 
 
 NCPAP Alone 
(397) 
Failed NCPAP (84) p-value 
Survival to day 3 370 (93.2%) 80 (95.2%) 0.489 
Survival to day 7 336 (84.6%) 71 (84.5%) 0.980 
Survival to 
discharge 
302 (76%) 49 (58.3%) 0.001 
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3.2 ≥1500g Group: 
There was a total of 1997 neonates weighing ≥ 1500g; 1570 infants did not receive NCPAP, 
154 had a major birth defect, 7 had insufficient information and 5 had NCPAP as a weaning 
mode from CMV.  There were thus 261 infants in the NCPAP group.  
The majority were males (164 (62.8%)).  Most of the infants were inborn (217 (83.1%)).  In 
129 (49.4%) infants the mode of delivery was by emergency caesarean section.  In the LBW 
(1501-2500g) category there were 220 (84.3%) infants and in the >2500g category there were 
41 (15.7%) infants.  The mean birth weight was 2044 grams (SD 528) with a maximum of 
5250 grams and the mean GA was 33.5 weeks (SD 2.9) with a minimum of 28 weeks.  249 
(95.4%) infants survived.  Surfactant was given to 210 (80.5%) of infants.  The mean 
duration of NCPAP was 1.62 days (SD 1.7) with a minimum of <1 day and a maximum of 31 
days.  There were 33 (12.6%) infants who failed NCPAP.  This group of larger infants 
represented 35.1% (261/742) of all the babies that received NCPAP over the study period.  
The respiratory diagnosis in the majority of cases was HMD (213 infants, 81.6%) but also 
included transient tachypnoea of the newborn (TTN), congenital pneumonia, meconium 
aspiration syndrome (MAS) and apnoea as shown in Table 4. 
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Table 4: Respiratory Diagnosis in ≥1500g group who received NCPAP 
 
Respiratory Diagnosis LBW <2500g >2500g 
TTN 8 (3.6%) 5 (12.2%) 
Congenital Pneumonia 9 (4.1%) 5 (12.2%) 
MAS 2 (0.9%) 10 (24.4%) 
HMD 200 (90.9%) 13 (31.7%) 
Apnoea 8 (3.6%) 1 (2.4%) 
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Chapter 4:  
Discussion 
This was the first study from our unit to study how we are using NCPAP in all our neonates 
from 750g to 5250g.  Previously we had investigated the use of NCPAP as it relates to the 
survival of both ELBW and VLBW infants in our unit but we have not determined the 
characteristics of the infants who are receiving NCPAP across all weight categories.   
 
The majority of the babies in the ELBW category (750-999g) received NCPAP (89.2%).  It is 
expected that all the babies in this weight category would have had HMD requiring NCPAP 
and surfactant replacement and it is encouraging that we managed to provide NCPAP to most 
patients.  However, NCPAP was not significantly associated with an improvement in survival 
in this group (p=0.261).  A previous study at our hospital which looked at the survival of 
ELBW infants also found that NCPAP was not associated with improved survival and that 
the most important determinants of survival were birth weight and gestational age [10].  Only 
16.1% of the ELBW infants and 18.2% of the VLBW infants (1000-1499g) failed NCPAP 
and were given ventilation.  However, in the ELBW category only infants >900g would have 
been offered CMV.  These figures are appropriate for a limited resources setting in a high 
care nursery such as ours.  We have only 9 Bubble NCPAP machines available but most of 
our babies were able to receive NCPAP.  This may be attributed to the fact that babies were 
able to wean off of the NCPAP relatively quickly allowing a high turnover of these machines.  
With the successful use of NCPAP far fewer premature babies are requiring NICU admission 
for ventilation.  This is both cost saving and prevents a large amount of morbidity and 
mortality that is associated with NICU.  Our ICU is shared between neonates, paediatrics and 
paediatric surgery patients.  There was a concern that lowering our ICU admission weight 
category to 900g would inundate the ICU with premature babies, but largely due to NCPAP 
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this has not been the case.  However, it is important to note that although babies that require 
NCPAP do not need NICU admission, they do require adequate high-care facilities with well-
trained nursing staff as they need close monitoring and active weaning of the NCPAP. 
 
In the larger ≥1500g babies, only 12.6% failed NCPAP.  In these babies we are using NCPAP 
for other indications such as TTN, congenital pneumonia, MAS and apnoea but in the 
majority of cases it is used for HMD in larger premature babies. 
It is disappointing to note that in this study there has been no improvement in the use of 
antenatal steroids since the study that was done at CMJAH in 2010 [11] (38.7% in this study vs 
36% in the 2010 study).  This is largely due to missed opportunities and late presentation 
once already in preterm labour [16]. 
 
The use of NCPAP was significantly associated with a higher mortality to day 7 (p<0.0005) 
and discharge (p<0.0005).    The increased mortality with NCPAP use may be due to other 
factors affecting survival such as late sepsis and NEC, which VLBW infants are prone to.  
There is also a selection bias as NCPAP is given to babies with more severe respiratory 
illness and not routinely offered to all premature babies.  Within the NCPAP group, NCPAP 
alone (without CMV) improved survival to discharge (p=0.001).  Prolonged ventilation is 
associated with increased morbidity and infants who fail NCPAP have a more severe degree 
of HMD with higher mortality.     
 
 Surfactant, BPD and late sepsis were shown to be significantly associated with the use of 
NCPAP.  The overall incidence of 22.4% BPD is higher than the 8.8% reported in our 
hospital in 2010 [11].  More babies are now offered NCPAP and surviving long enough to 
develop BPD than in 2010 where over a one year period only 96/474 (20.3%) VLBW infants 
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received NCPAP.  VLBW infants are prone to late onset sepsis [17] and the use of NCPAP has 
also been associated with late onset sepsis [18].  Limited nursing staff and overcrowding in the 
neonatal nursery further compound this problem.  
 
There was a very low rate of complications of NCPAP in our study with only 5/481 infants 
developing a pneumothorax, and 27/481 infants developing nasal septal necrosis, while IVH 
was not found to be significantly associated with NCPAP.  When compared to the Vermont 
Oxford Network (VON), our rate of pneumothoraces is lower (1% vs 4%) and our NCPAP 
use (67.7% vs 73.5%) is also lower than theirs. 
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Chapter 5:  
Conclusion 
NCPAP is cost effective and easy to use in a resource limited environment with a small 
number of Bubble NCPAP machines being able to treat a large number of neonates with 
HMD.  This effectively releases ICU beds thereby increasing the number of beds that are 
available for ventilatory support for our neonatal and general paediatric patients.  NCPAP can 
be administered to neonates with HMD in a high-care nursery environment with adequately 
trained nurses such as in a level 2 hospital.  This would decrease the burden on tertiary level 
hospitals both for NCPAP administration and for NICU admissions for babies with HMD 
who have respiratory failure.  More resources need to be dedicated to patient education and 
access to sufficient antenatal care in order to decrease the number of premature deliveries.  
More could be done to improve our rates of antenatal steroid administration but for this to be 
effective our patients need to access our healthcare facilities timeously and this depends on 
improved patient education and transport to our hospitals.    
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Chapter 6:  
Limitations and Recommendations 
 
The retrospective design of this study was a limitation as a number of the neonatal records in 
the database were incomplete.  Due to this some of the records had to be excluded based on 
inadequate available information.  Human error also plays a role, as on entering the records 
into the database certain dates were sometimes entered incorrectly.  This resulted in 
inaccurate lengths of stay or inaccurate estimates of the amount of time that the neonates’ 
spent on NCPAP or on ventilation.  The date of starting NCPAP was very important as we 
only wanted to look at babies where NCPAP was started within 72 hours of birth.  Some 
cases were difficult to identify due to a lack of information in the neonatal record as well as 
an inability to verify the diagnosis where information was incomplete.   
 
A considerable number of studies have shown that NCPAP administered to premature infants 
with HMD results in a significant improvement in survival.  It is recommended that further 
prospective studies be done on NCPAP outcomes in our local hospitals.   
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